A dose-ranging, randomized, double-blind, parallel-group, placebo-controlled, multi-center study of R05313534 used as add-on to donepezil treatment in patients with mild to moderate symptoms of Alzheimer’s disease.    

Año: 2009

Investigador: Investigadora Principal: Dra. Mercè Boada Rovira

Código de protocolo: WN22018

Estudios Clínicos Farmacológicos

 Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease (esipad): LY450139.

Año: 2009

Investigador: Investigadora Principal: Dra. Mercè Boada Rovira

Código de protocolo: H6L-MC-LFAN

Estudios Clínicos Farmacológicos

A 24-week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to investigate the safety and efficacy of SB-742457 When Added to Existing Donepezil Treatment in Subjects with Mild to Moderate Alzheimer’s Disease.

Año: 2009

Investigador: Investigadora Principal: Dra. Mercè Boada Rovira

Código de protocolo: AZ3110866

Estudios Clínicos Farmacológicos

Open-Label Extension Study of 23 Mg Donepezil Sustained Release in Patients with Moderate to Severe Alzheimer’s Disease.

Año: 2009

Investigador: Investigadora Principal: Dra. Mercè Boada Rovira

Código de protocolo: E-2020-G000-328

Estudios Clínicos Farmacológicos

A phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001-ELN115727) in Subjects with Mild to Moderate Alzheimer’s Disease Who Are Apoliprotein Eε4 Non-Carriers.

Año: 2009

Investigador: Investigadora Principal: Dra. Mercè Boada Rovira

Código de protocolo: 3133K1-3000-WW

Estudios Clínicos Farmacológicos

A 76-week prof¡spective, open-label, multicenter study to evaluate the long-term of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson's Disease

Año: 2009

Investigador: Investigadora Principal: Dra. Mercè Boada Rovira

Código de protocolo: CENA713B2315

Estudios Clínicos Farmacológicos

A 52-Weeks Open-Label Extension Study of the Long-Term Safety and Efficacy of Rosiglitazone Extended-Release (RSG XR) as Adjunctive Therapy to Acetylcholiesterase Inhibitors in Subjects with Mild-to-Moderate Alzheimer's Disease 8REFLECT-4).

Año: 2009

Investigador: Investigadora Principal: Dra. Mercè Boada Rovira

Código de protocolo: AVA 102675

Estudios Clínicos Farmacológicos

Cognitive Effects, Safety, Tolerabiloty and Phamacokinetics of AZD3480 vs. Donepezil (Aricept) and Placebo. A Multi-centre, Double.blind, Randomized, Mild to Moderate Alzheimer's Disease During 3 Months of Treatment (Siroco)

Año: 2009

Investigador: Investigadora Principal: Dra. Mercè Boada Rovira

Código de protocolo: D3690C00010

Estudios Clínicos Farmacológicos